Skip to main content
SKYE logo

SKYE · Skye Bioscience, Inc.

Track SKYE — free
$0.42 -0.09 (-17.23%) At close · Aug 17
Market Cap
$17.76M
Shares
35.42M

Skye Bioscience, Inc. Earnings Call Transcripts

Every quarterly earnings call for Skye Bioscience, Inc. (SKYE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q4
2026-03-10
Skye Bioscience, Inc. Q4 FY2025 Earnings Call
Positive tone CBEYOND clinical data and combination results Exposure/PK and biodistribution rationale Namasimab CB1 mechanism and differentiation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Skye Bioscience, Inc. Q3 FY2025 Earnings Call
Confident tone CBEYOND Phase 2a top-line results Discovery R&D and CB1 mechanism Dose-ranging strategy and higher doses
Diluted EPS
$-0.32
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Skye Bioscience, Inc. Q2 FY2025 Earnings Call
Confident tone Combination efficacy with tirzepatide Phase IIa clinical progress and timeline Market access and KOL feedback
Diluted EPS
$-0.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Skye Bioscience, Inc. Q1 FY2025 Earnings Call
Positive tone Nimacimab Preclinical Data and Differentiation Combination Strategy with GLP-1 Phase 2b Trial Design
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Skye Bioscience, Inc. Q4 FY2024 Earnings Call
Confident tone nimacimab CBeyond clinical trial Safety profile and DSMB reviews Accelerated topline data timeline
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Skye Bioscience, Inc. Q3 FY2024 Earnings Call
Confident tone Preclinical data and ObesityWeek disclosure GLP-1 / incretin landscape and combination potential Phase 2 CBeyond obesity clinical trial execution
Diluted EPS
$-0.10
Audio Transcript Slides 8-K10-Q
Showing 1–6 of 6 earnings calls
Key facts CIK 1516551 CUSIP 83086J200 13F (30d) 43 filings 43 filers Visit website Investor relations